Phaos Technology Holdings (Cayman) (POAS) Cash & Equivalents (2024 - 2025)
Phaos Technology Holdings (Cayman)'s (POAS) quarterly Cash & Equivalents came in at $42673.9 in Q4 2025, down 55.97% on a QoQ basis from $96918.3 in Q2 2025.
Phaos Technology Holdings (Cayman) (POAS) Cash & Equivalents (2024 - 2025) Analysis & Trends
Phaos Technology Holdings (Cayman) (POAS) has 2 years of Cash & Equivalents data on file, last reported at $42673.9 in Q4 2025.
- Quarterly Cash & Equivalents changed N/A year-over-year to $42673.9 in Q4 2025, while the trailing twelve-month figure through Oct 2025 was $42673.9 (changed N/A YoY) and the FY2025 annual result came in at $97007.0, down 94.35% from the prior year.
- Cash & Equivalents slipped to $42673.9 in Q4 2025, from $96918.3 in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $1.7 million in Q2 2024 to a low of $42673.9 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 5.10 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 3.39 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 1.95 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 539.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 2.91 Bn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 1.11 Bn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 2.11 Bn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 3.25 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 482.30 Mn |
| 10 | Phaos Technology Holdings (Cayman) | 4.06 Mn | 4.02 Mn | - | 42,673.91 |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | 42,673.91 |
| Apr 30, 2025 | 96,918.26 |
| Apr 30, 2024 | 1.72 Mn |